EVP, Innovative Medicine, R&D · JOHNSON & JOHNSON (JNJ)

John Reed

A named executive officer of JOHNSON & JOHNSON in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$12,214,062

FY2024: $9,304,430

4th of 5 named executive officers at Johnson & Johnson by FY2025 total.

5 named officers on file for JOHNSON & JOHNSON, FY2025

See an example →

What this number hides

The filing gives the total. JOHNSON & JOHNSON’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how JOHNSON & JOHNSON’s whole pay program stands against its peers

  • JOHNSON & JOHNSON’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JNJ→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 11, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-10.

Free

Get John Reed’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track John Reed and every company like it: Velarion Intel, free for 3 days, no card →

John Reed compensation by year

JOHNSON & JOHNSON Summary Compensation Table · all 3 fiscal years held
In US dollars, as JOHNSON & JOHNSON reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$840,385$1,192,308$1,220,308
Bonus$5,700,000$0$0
Stock awards$11,699,934$3,953,124$6,160,665
Option awards$0$1,802,995$2,430,013
Non-equity incentive$1,720,000$1,725,000$1,810,000
Pension and deferred compensation$374,000$441,000$458,000
All other$313,031$190,003$135,076
Total$20,647,350$9,304,430$12,214,062

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: JOHNSON & JOHNSON DEF 14A filed March 11, 2026, accession 0000200406-26-000063, and prior-year filings. Open the filing on EDGAR.

How this page was built: the JOHNSON & JOHNSON filed document, accession 0000200406-26-000063. Every figure is read from that document and cited to the page and table it appears in. Filed March 11, 2026.

$20.6M
$9.3M
$12.2M
FY23
FY24
FY25
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU53,968$11,205,376—
RSU30,749$6,384,415—
RSU25,255$5,243,696—
RSU5,539$1,150,063—
RSU2,698$560,186—
Option43,442—$157.92
Option89,781—$156.15

Per the Outstanding Equity Awards at Fiscal Year-End table in JOHNSON & JOHNSON's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2025 proxy (filed March 11, 2026)
current to 2026-11-10 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-01Tax withholding—11,002$229.8524,911
2026-05-01Exercise or conversion—25,255$0.0035,913
2026-05-01Exercise or conversion derivative—25,255$0.000

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

JOHNSON & JOHNSON’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Joaquin DuatoChairman/CEO$32,758,111
Joseph WolkEVP, CFO$14,405,442
Jennifer TaubertEVP, WWC Innovative Medicine$14,030,063
John Reed · this pageEVP, Innovative Medicine, R&D$12,214,062
Tim SchmidEVP, WWC, MedTech$9,336,765

John Reed's compensation dossier, JOHNSON & JOHNSON

You have read John Reed's totals and holdings. The dossier adds each equity grant JOHNSON & JOHNSON disclosed for John Reed and JOHNSON & JOHNSON's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full JOHNSON & JOHNSON compensation record

free company brief

This page is one person within JOHNSON & JOHNSON's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the JOHNSON & JOHNSON proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order JOHNSON & JOHNSON's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are JOHNSON & JOHNSON's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order JNJ

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

John Reed's compensation dossier